[1] Zhan C, Peng Y, Ye H. et al. Triglyceride glucose-body mass index and cardiovascular mortality in patients undergoing peritoneal dialysis: a retrospective cohort study[J]. Lipids Health Dis, 2023,22(1):143. DOI: 10.1186/s12944-023-01892-2.
[2] Sarnak MJ, Amann K, Bangalore S, et al. Chronic kidney disease and coronary artery disease: JACC state-of-the-art review[J]. J Am Coll Cardiol, 2019,74(14):1823-1838.DOI: 10.1016/j.jacc.2019.08.1017.
[3] Kalkan S, Cagan Efe S, Karagöz A,et al. A new predictor of mortality in ST-elevation myocardial infarction: the uric acid albumin ratio[J]. Angiology, 2022,73(5):461-469.DOI: 10.1177/00033197211066362.
[4] Çakmak EÖ, Bayam E, Çelik M,et al. Uric acid-to-albumin ratio: a novel marker for the extent of coronary artery disease in patients with non-ST-elevated myocardial infarction[J]. Pulse (Basel), 2021 ,8(3-4):99-107.DOI: 10.1159/000514533.
[5] Stevens PE, Levin A; Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline[J]. Ann Intern Med, 2013,158(11):825-830. DOI: 10.7326/0003-4819-158-11-201306040- 00007.
[6] Bello AK, Okpechi IG, Osman MA,et al. Epidemiology of peritoneal dialysis outcomes[J]. Nat Rev Nephrol, 2022,18(12):779-793.DOI: 10.1038/s41581-022-00623-7.
[7] 柯婷雯,叶钊,杜雅钦,等. 血清Hcy及FGF-23预测血液透析治疗尿毒症合并高血压患者并发心脑血管事件的价值[J]. 国际医药卫生导报,2024,30(15):2500-2506. DOI:10.3760/cma.j.issn.1007-1245.2024.15.008.
[8] Hahr AJ, Molitch ME. Management of diabetes mellitus in patients with CKD: core curriculum 2022[J]. Am J Kidney Dis, 2022 ,79(5):728-736. DOI: 10.1053/j.ajkd.2021. 05.023.
[9] Wen Y, Guo Q, Yang X, et al. High glucose concentrations in peritoneal dialysate are associated with all-cause and cardiovascular disease mortality in continuous ambulatory peritoneal dialysis patients[J]. Perit Dial Int, 2015,35(1):70-77.DOI: 10.3747/pdi.2013.00083.
[10] Burnier M, Damianaki A. Hypertension as cardiovascular risk factor in chronic kidney disease[J]. Circ Res, 2023,132(8):1050-1063.DOI: 10.1161/CIRCRESAHA.122. 321762.
[11] Gupta A, Nagaraju SP, Bhojaraja MV,et al. Hypertension in chronic kidney disease: an update on diagnosis and management[J]. South Med J, 2023,116(2):237-244. DOI: 10.14423/SMJ.0000000000001516.
[12] Wu J, Zhan X, Wen Y,et al. Preexisting cardiovascular disease, hypertension, and mortality in peritoneal dialysis[J]. Rev Cardiovasc Med, 2023,24(1):30.DOI: 10.31083/j.rcm2401030.
[13] Mikolasevic I, Žutelija M, Mavrinac V,et al. Dyslipidemia in patients with chronic kidney disease: etiology and management[J]. Int J Nephrol Renovasc Dis, 2017,10:35-45.DOI: 10.2147/IJNRD.S101808.
[14] Cai K, Luo Q, Zhu B,et al. Neutrophil-lymphocyte ratio is associated with arterial stiffness in patients with peritoneal dialysis[J]. BMC Nephrol, 2016,17(1):191. DOI: 10.1186/s12882-016-0394-4.
[15] Wen Y, Zhan X, Wang N,et al. Monocyte/lymphocyte ratio and cardiovascular disease mortality in peritoneal dialysis patients[J]. Mediators Inflamm, 2020,2020:9852507. DOI: 10.1155/2020/9852507.
[16] Kiebalo T, Holotka J, Habura I,et al. Nutritional status in peritoneal dialysis: nutritional guidelines, adequacy and the management of malnutrition[J]. Nutrients, 2020,12(6):1715.DOI: 10.3390/nu12061715.
[17] Saito Y, Tanaka A, Node K, et al. Uric acid and cardiovascular disease: a clinical review[J]. J Cardiol, 2021,78(1):51-57.DOI: 10.1016/j.jjcc.2020.12.013.
[18] Kimura Y, Tsukui D, Kono H. Uric acid in inflammation and the pathogenesis of atherosclerosis[J]. Int J Mol Sci,2021,22(22):12394. DOI: 10.3390/ijms222212394.
[19] Manolis AA, Manolis TA, Melita H,et al. Low serum albumin: a neglected predictor in patients with cardiovascular disease[J]. Eur J Intern Med, 2022,102:24-39. DOI: 10.1016/j.ejim.2022.05.004.
[20] Selçuk M, Çınar T, Şaylık F,et al. Predictive value of uric acid/albumin ratio for the prediction of new-onset atrial fibrillation in patients with ST-elevation myocardial infarction[J]. Rev Invest Clin, 2022,74(3):156-164.DOI: 10.24875/RIC.22000072.
[21] Li S, Chen H, Zhou L,et al. The uric acid to albumin ratio: a novel predictor of long-term cardiac mortality in patients with unstable angina pectoris after percutaneous coronary intervention[J]. Scand J Clin Lab Invest, 2022,82(4):304-310.DOI: 10.1080/00365513.2022.2084698.
[22] Azechi T, Kanehira D, Kobayashi T,et al. Trichostatin A, an HDAC class I/II inhibitor, promotes Pi-induced vascular calcification via up-regulation of the expression of alkaline phosphatase[J]. J Atheroscler Thromb, 2013,20(6):538-547. DOI: 10.5551/jat.15826.
[23] Bover J, Ureña P, Aguilar A,et al. Alkaline phosphatases in the complex chronic kidney disease-mineral and bone disorders[J]. Calcif Tissue Int, 2018,103(2):111-124.DOI: 10.1007/s00223-018-0399-z.
[24] Haarhaus M, Cianciolo G, Barbuto S,et al. Alkaline phosphatase: an old friend as treatment target for cardiovascular and mineral bone disorders in chronic kidney disease[J]. Nutrients, 2022,14(10):2124.DOI: 10.3390/nu14102124.
[25] Hwang SD, Kim SH, Kim YO,et al. Serum alkaline phosphatase levels predict infection-related mortality and hospitalization in peritoneal dialysis patients[J]. PLoS One, 2016,11(6):e0157361.DOI: 10.1371/journal.pone.0157361.
|